In the present study, the bioactivities of eight selected Kampo formulations that are currently in clinical use for the treatment of diabetes complications were assessed using human AR (hAR) inhibitory activity as the primary parameter to explore their possible novel clinical applications in the treatment of diabetes complications. This evidence concerns the gene AR and diabetes mellitus.